AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

The Wall Street JournalView source article

Part of story

AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug collaboration

AstraZeneca is investing $2 billion in Summit Therapeutics and collaborating on clinical trials testing their cancer treatments together, with AstraZeneca taking an equity stake in the biotech company.

Sep 28, 20265 sourcesPharma Drug Approval and Clinical Trials Clinical trials Cancer treatment breakthroughs

AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug collaboration

Other sources for this story

Bloomberg

Summit Therapeutics Jumps on $2 Billion AstraZeneca Investment

The Wall Street Journal

Summit Shares Surge on $2 Billion AstraZeneca Investment

Reuters

AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up | Reuters

Endpoints

AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

Part of story

AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug collaboration

Other sources for this story

Summit Therapeutics Jumps on $2 Billion AstraZeneca Investment

Summit Shares Surge on $2 Billion AstraZeneca Investment

AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up | Reuters

AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug

AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

Part of story

AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug collaboration

Other sources for this story

Summit Therapeutics Jumps on $2 Billion AstraZeneca Investment

Summit Shares Surge on $2 Billion AstraZeneca Investment

AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up | Reuters

AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug